GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TRACON Pharmaceuticals Inc (NAS:TCON) » Definitions » Cyclically Adjusted Price-to-FCF

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is TRACON Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


TRACON Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TRACON Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

TRACON Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TRACON Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



TRACON Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

TRACON Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, TRACON Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.264/129.4194*129.4194
=-0.264

Current CPI (Dec. 2023) = 129.4194.

TRACON Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 134.650 99.695 174.797
201406 -26.833 100.560 -34.534
201409 -25.733 100.428 -33.162
201412 -52.783 99.070 -68.953
201503 -120.050 99.621 -155.959
201506 -56.233 100.684 -72.282
201509 -58.131 100.392 -74.939
201512 -124.066 99.792 -160.900
201603 -109.361 100.470 -140.872
201606 -154.984 101.688 -197.250
201609 -82.672 101.861 -105.039
201612 -84.296 101.863 -107.100
201703 -93.469 102.862 -117.601
201706 -56.940 103.349 -71.303
201709 15.500 104.136 19.263
201712 -26.341 104.011 -32.776
201803 -68.736 105.290 -84.489
201806 -68.302 106.317 -83.144
201809 -41.779 106.507 -50.767
201812 -54.537 105.998 -66.588
201903 -47.322 107.251 -57.104
201906 -38.487 108.070 -46.090
201909 -43.887 108.329 -52.431
201912 -26.854 108.420 -32.055
202003 -20.432 108.902 -24.282
202006 -12.085 108.767 -14.380
202009 -8.131 109.815 -9.583
202012 -4.685 109.897 -5.517
202103 -6.283 111.754 -7.276
202106 -5.419 114.631 -6.118
202109 -9.097 115.734 -10.173
202112 -5.265 117.630 -5.793
202203 -6.884 121.301 -7.345
202206 -7.916 125.017 -8.195
202209 -6.369 125.227 -6.582
202212 -4.177 125.222 -4.317
202303 -4.222 127.348 -4.291
202306 -3.802 128.729 -3.822
202309 8.167 129.860 8.139
202312 -0.264 129.419 -0.264

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TRACON Pharmaceuticals  (NAS:TCON) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


TRACON Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


TRACON Pharmaceuticals (TRACON Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
Executives
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Charles Theuer director, officer: President and CEO C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Bonne J. Adams officer: Chief Operating Officer C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Scott B. Brown officer: Chief Accounting Officer (PAO) C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
William R Larue director C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122
Carol C. Lam director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122
Saundra L Pelletier director C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Johnson-pratt director C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Ikarian Healthcare Master Fund, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Mark C Wiggins officer: Chief Business Officer 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Neil Shahrestani 10 percent owner, other: Member of 10% Group 12806 WINDING CREEK DRIVE, FRISCO TX 75035
Ikarian Healthcare Fund Gp, L.p. 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Chart Westcott Living Trust 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201
Ikarian Capital, Llc 10 percent owner, other: Member of 10% Group 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201
Puissance Cross-border Opportunities V Llc 10 percent owner 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022

TRACON Pharmaceuticals (TRACON Pharmaceuticals) Headlines

From GuruFocus

Could Insider Buying Signal that TRACON Pharmaceuticals Inc Is Undervalued?

By GuruFocus Research GuruFocus Editor 09-26-2022